Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deputy Asia Editor
India
+20 year(s) experience
Anju has extensive experience at India's mainstream financial dailies, The Economic Times, The Hindu Business Line and The Financial Express. As Corporate Bureau Chief (Mumbai), she led a team of reporters at The Financial Express prior to joining Scrip. She’s been associated with Scrip since 2001, when it was part of PJB Publications.
Anju enjoys covering pharma conferences and interviewing industry heads and regulatory/government officials in the region. Occasionally, she also moderates industry panels at key events.
She follows racket sports closely and has previously received recognition at the national level in India. She loves the hills and when not reporting on pharma believes that nature is the best therapy.
Scrip
The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.
Scrip
SaNOtize is to start Phase III trials for its nitric oxide nasal spray for COVID-19 and hopes to enlist volunteers from several countries, including India. The Canadian firm claims initial studies have demonstrated effectiveness across SARS-CoV-2 mutations, with plans afoot to validate it against the spreading Delta variant.
Scrip
In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.
In Vivo
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Generics Bulletin
Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.
Topic Coronavirus Drug Review
Generics Bulletin
Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.
Scrip
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up
Topic Vaccines Coronavirus
Scrip
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.
Topic Coronavirus Vaccines
Scrip
The coronavirus pandemic could dull pharma M&A activity in the short-term as companies hoard cash and prioritize core activities. But experts say stress in the system could potentially push some firms to cull surplus assets or seek financial/strategic investors, amid a generally tough funding environment. Private equity investors may also find attractive investment opportunities to pursue.
Topic Coronavirus
Scrip
Parexel executives tell Scrip about the company’s efforts in tandem with sponsors to navigate the challenging clinical research environment amid COVID-19. A renewed interest for decentralized trials or hybrid approaches and the use of remote monitoring and telehealth visits to keep studies moving are some of the key initiatives.
Topic Coronavirus
Scrip
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
Topic Coronavirus
Scrip
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Generics Bulletin
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
Pink Sheet
Courts may increasingly find limits on how far Park Doctrine tool can be ‘pushed,’ Sklamberg says in wide-ranging interview with the Pink Sheet. Former US FDA deputy commissioner for global regulatory operations and policy, now with law firm Akin Gump, also shares his views on the US-EU MRA to recognize each other’s inspections and data integrity.
Topic FDA
Scrip
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Generics Bulletin
30 Jul 2021
Generics Bulletin
27 Jul 2021
Scrip
23 Jul 2021
Scrip
19 Jul 2021
Scrip
16 Jul 2021
Scrip
14 Jul 2021
Scrip
12 Jul 2021
Scrip
09 Jul 2021
Scrip
01 Jul 2021
Scrip
28 Jun 2021
Scrip
23 Jun 2021
Scrip
21 Jun 2021
Scrip
16 Jun 2021
Scrip
01 Jun 2021
Generics Bulletin
01 Jun 2021
